Randomized trial · people
Teriparatide then denosumab: spine density up 18.3% over 4 years
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this trial, the order mattered: going from teriparatide to denosumab kept bone density rising, while going from denosumab to teriparatide gave smaller gains at the hip and a loss at the wrist.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 77
- Published
- 2015
- Journal
- Lancet
What they tested
The team set out to test how bone density changes when women with osteoporosis after menopause switch between teriparatide and denosumab.
How the study was done
A randomized controlled extension of the DATA trial in 77 women with osteoporosis after menopause. After 24 months on teriparatide, denosumab or both, they switched treatments for 24 more months: teriparatide to denosumab, denosumab to teriparatide, or the combination to denosumab alone.

What they found
Over 4 years, spine bone mineral density (BMD) rose 18.3% in the teriparatide to denosumab group, 14.0% in the denosumab to teriparatide group and 16.0% in the combination to denosumab group. These spine differences were not statistically significant. Total hip BMD rose 6.6% after teriparatide to denosumab, compared with 2.8% after denosumab to teriparatide, and 8.6% in the combination to denosumab group. Wrist (radius) BMD was unchanged at 0.0% after teriparatide to denosumab, fell 1.8% after denosumab to teriparatide, and rose 2.8% in the combination to denosumab group.
What it doesn’t show
The groups were small, with 23 to 27 women each, and the study measured bone density and bone turnover markers, not fractures. It was funded in part by Amgen and Eli Lilly.
The paper
Leder et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015.
The compound
More studies on Teriparatide
- Abaloparatide, teriparatide beat other drugs on spine BMD in menMeta-analysis · people · 2025
- Teriparatide cut fracture risk vs bisphosphonates (RR 0.61)Meta-analysis · people · 2024
- Abaloparatide: larger hip BMD gains than teriparatide at 24 weeksMeta-analysis · people · 2023
- Teriparatide: more bony union at 6 months than zoledronate after PLIFRandomized trial · people · 2022
- Teriparatide: 45.4% of jaw osteonecrosis lesions resolved by 52 weeksRandomized trial · people · 2020
- Teriparatide: fewer new vertebral fractures than risedronate in VERORandomized trial · people · 2018
- Every study on Teriparatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.